Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01565850 · ClinicalTrials.gov registry record · Phase 2
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT01565850 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 153 participants.
The verdict
NCT01565850, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA \< 50 copies/mL at Week 24.
Interventions
- DRUG FTC/TDF
- DRUG DRV
- DRUG COBI
- DRUG D/C/F/TAF
- DRUG D/C/F/TAF Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01565850
The ClinicalTrials.gov registry entry for NCT01565850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which FTC/TDF is the first listed.
NCT01565850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01565850 about?
NCT01565850 is a clinical study titled "D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults". This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naiv...
What is the current status of trial NCT01565850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2012-04. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01565850?
The interventions under investigation include: FTC/TDF (DRUG), DRV (DRUG), COBI (DRUG), D/C/F/TAF (DRUG), D/C/F/TAF Placebo (DRUG).
Who is sponsoring clinical trial NCT01565850?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.